Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 301–400 of 657
mukhlif, B. A., Ullah, M. I., Uthirapathy, S., Menon, S. V., Sharma, R. S. K., KADHIM, A. J., Sharma, S., Juneja, B., Abosaoda, M. K., & Kadhum, W. R. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-024-09960-2 · Cited by 10
“The efficiency of passive targeting via the EPR effect is influenced by several factors related to the properties of the nanoparticles, the characteristics of the tumor, and the overall physiological environment [40].”
Du, S., Wu, K., Guan, Y., Lin, X., Gao, S., Huang, S., Shi, X., Wang, L., Chen, X., & Chen, T. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125221 · Cited by 8
John, C., Jain, K., Masanam, H. B., Narasimhan, A. K., & Natarajan, A. (2022) · Micromachines · doi:10.3390/mi13122217 · Cited by 8
“NPs are a flexible platform to use in cancer immunotherapy, displaying potential in a variety of fields such as imaging and drug delivery without harming another internal system [19].”
BackgroundBiabangard, A., Asoodeh, A., Jaafari, M. R., & Moosavi, F. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116470 · Cited by 8
Zerumbone delivery to tumor cells via pH-sensitive polymeric micelles
Duong, N. T., Thiet, T. D., Anh, T. T. P., Lan, P. T., Anh, N. T., & Лам, Т. Д. (2023) · Colloid & Polymer Science · doi:10.1007/s00396-023-05191-1 · Cited by 9
“Furthermore, the passive targeting of tumors through the EPR effect relies on the leaky vasculature and poor lym - phatic drainage of tumors [34–36].”
The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression
Reeva, H., Mahesh, G., Manjunath, U., Selvamurugan, N., & Mohankumar, D. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152346 · Cited by 7
Esperouz, F., Lorusso, M., Santarelli, A., LILLO, A. D., Muzio, L. L., Ciavarella, D., & Russo, L. L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1619560 · Cited by 7
Jang, J. Y., Kim, D., Im, E., Lee, N. K., & Kim, N. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199433 · Cited by 8
“…spurred the exploration of nanotech-nology-based delivery approaches, including polymeric nanoparticles, liposomes, and solid lipid nanoparticles that can enhance bioavailability, prolong circulation time, and increase tumor selectivity via enhanced permeability and retention effect [90,92–94].”
Lakshmikanthan, M., Muthu, S., Krishnan, K., Altemimi, A. B., & Abedelmaksoud, T. G. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102935 · Cited by 9
Alsaikhan, F., Al-Saikhan, T., & Alsaikhan, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s596646 · Cited by 7
“18,19 However, human tumor studies reveal substantially greater EPR variability than animal models, with elevated interstitial fluid pressure and dense extracellular matrix further limiting tumor penetration.”
Feye, J., Matthias, J., Fischer, A., Rudolph, D., Treptow, J., Popescu, R., Franke, J., Exarhos, A. L., Boekelheide, Z. A., Gerthsen, D., et al. (2023) · Small · doi:10.1002/smll.202301997 · Cited by 10
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Silli, E. K., Zheng, Z., Zhou, X., Li, M., Tang, J., Guo, R., Tan, C., & Wang, Y. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01455-x · Cited by 7
“The best particle sizes for passing through the endothelial barrier and getting into tumor tissues are those around 100 to 200 nm [16].”
Revolutionizing lung cancer treatment with smart pulmonary drug delivery nanosystems
Gamal, O., Agamey, A. T., Mohamed, Z. A., & El-sherbiny, I. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106158 · Cited by 7
Leflunomide nanocarriers: a new prospect of therapeutic applications
Zewail, M. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2407373 · Cited by 7
“Passively targeted medications that rely on the ePR effect may not be enough to accomplish successful targeting at the desired locations therefore active targeting approach is more effective in ensuring drug localisation at tumour sites (Subhan et al .”
Lin, J., Shuyuan, Z. H. O. U., Hairong, X. I. A. N., Weiming, C. H. E. N., Zhang, Y., ZHANG, W., Zhihong, G. U. A. N., & Mei, W. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00057-2 · Cited by 7
Exploring the Theranostic Applications and Prospects of Nanobubbles
Shah, R., Phatak, N., Choudhary, A., Gadewar, S., Ajazuddin, M., & Bhattacharya, S. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010248189231010085827 · Cited by 7
A pH-Responsive Protein Assembly through Clustering of a Charge-Tunable Single Amino Acid Repeat
Bae, J., & Kim, H. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c07269 · Cited by 7
A comprehensive review on lipid-based nanoparticles via nose to brain targeting as a novel approach
Hameed, H., Faheem, S., Younas, K., Jamshaid, M., Ereej, N., Hameed, A., Munir, R., & Khokhar, R. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2404414 · Cited by 7
“…of nanoparticles from the blood arteries, their diffusion into the tumour tissues, as well as their interactions with intra-cellular or extra-cellular targets with the tumour’s micro-environment are three interrelated mechanisms by which the ePR effect alters molecular distribution (Subhan et al .”
Stimuli-responsive nanoparticles: a novel approach for melanoma treatment
Rout, B., Maharana, S. K., & Jain, A. (2025) · Journal of Nanoparticle Research · doi:10.1007/s11051-025-06231-3 · Cited by 7
“Although func-tionalizing NPs with targeting ligands can prevent this issue, most functionalization processes are inherently difficult [30].”
Ben‐Haim, A. E., Shalev, N., Amalraj, A. J. J., Zelinger, E., Mani, K. A., Belausov, E., Shoval, I., Nativ‐Roth, E., Maria, R., Atkins, A., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140822 · Cited by 7
Lim, J. X., Yong, Y. K., Dewi, F. R. P., Chan, S. Y., & Lim, V. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01790-3 · Cited by 8
“…a chance for the EPR [103]; although however, the performance of the nanoparticles is relatively limited by the insufficient EPR, which is attributed to tumour heterogeneity, the variabilities of the tumour microenvironment, variations of the vascular permeability system among tumour growths [103].”
InfluentialStudy of doxorubicin release carried out by pH-responsive chitosan-alginate hydrogels
Oliveira, T. P., da Silva, J. G. V., Costa, P. M., de Oliveira, M. C. D., Coelho, R. C., Nascimento, A. M. S. S., Silva-Filho, E. C., dos Santos, F. E. P., & Muniz, E. C. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127523 · Cited by 7
Samir, N., Özerkan, D., Kalındemirtaş, F. D., Kariper, İ. A., Bulut, H., Kuruca, S. E., Altuner, E. M., & Ulukaya, E. (2023) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-023-09725-6 · Cited by 7
Majeed, S., Cui, G., Liu, Y., Khan, A. M., Liu, W., Wang, X., & Wu, Z. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c01798 · Cited by 6
Martins, J. C., do Amaral, M. K. O., Amaral, I. M. D. M., Oliveira, A. C. D. J., Leão, A. D., Chaves, L. L., Soares, M. F. D. L. R., & Soares‐Sobrinho, J. L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149448 · Cited by 8
Tumor agnostic drug delivery with dynamic nanohydrogels
Housley, S. N., Bourque, A. R., Matyunina, L. V., Panicker, I., Echeverri, E. S., Izykowicz, M. M., Herrmann, O. A., Lee, S., Arboleda, J. C., Jamali, V., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-66788-4 · Cited by 6
Liposomal nanocarriers in precision oncology: Advances and prospects
Li, Y. F., & Zhou, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105236 · Cited by 7
Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer
Macadangdang, R. R., Agrawal, R., Bhushan, B., Garg, A., Singh, K., Kumar, S., & Kumar, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010279483240417050548 · Cited by 7
Fundamentals behind the success of nanotechnology in cancer treatment and diagnosis
Chowdhury, M. M. H., Kubra, K., & Islam, A. (2024) · OpenNano · doi:10.1016/j.onano.2024.100215 · Cited by 6
Nanomaterials in Medicine: Advancing Drug Delivery, Diagnostics, and Therapeutics
Kader, N. S. A. (2024) · Journal of Basic and Applied Research in Biomedicine · doi:10.51152/jbarbiomed.v10i1.239 · Cited by 8
Kaur, C., Villarreal, E., Cabe, M. H., & Langert, K. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-96231-z · Cited by 7
Advancements in Nanosuspension Technology for Drug Delivery
Hanwate, R. M., Babu, R. H., Wadhave, P. A. W. P. A., & Mishra, V. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00368-4 · Cited by 6
“Formu-lations for dermal delivery have shown promising results in treating skin diseases, infections, and inflammatory conditions by providing sustained drug release and improved drug retention at the target site [20].”
Kronberger, J., Balber, T., Schueffl, H. H., Wahrmann, R., Federa, A., Gradl, M., Brandt, M., Wanek, T., Mitterhauser, M., Kowol, C. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00803 · Cited by 6
Islam, R., Kotalík, K., Šubr, V., Gao, S., Zhou, J.-R., Yokomizo, K., Etrych, T., & Fang, J. Q. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102636 · Cited by 7
Hasan, U., Chauhan, M. K., Basu, S. M., Jayakumar, R., & Giri, J. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01401-z · Cited by 6
Inorganic and metal-based nanoparticles
Paul, G., Gupta, U., Shah, H., Mazahir, F., & Yadav, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91924-1.00006-x · Cited by 7
Chen, L., Zhang, Z., Liu, Y., Liu, C., Xiao, C., Gong, L., Jin, M., Gao, Z., & Huang, W. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110228 · Cited by 7
Harisa, G. I., Bakheit, A. H. H., Alshehri, S., Attia, S. M., & Attia, M. S. M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09757-2 · Cited by 6
“Moreover, the nanoscale materials could deposited in the tumor tissues at about 10-to-100-fold higher concentrations compared to free drugs [43].”
AlMotwaa, S. M., & Al‐Otaibi, W. A. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2386287 · Cited by 6
“The rapid vascularisation required for the formation of malignant tumours causes a weak and leaky vasculature in addition to insufficient lymphatic drainage, which is what enables the EPR effect (Subhan et al. 2021).”
Reviansyah, F. H., Putra, D., Supriatna, J., Takarini, V., & Komariah, M. (2024) · Cancer Management and Research · doi:10.2147/cmar.s477791 · Cited by 6
“50 By specifically targeting the tumor and utilizing the naturally leaking vasculature of the tumor to enhance the accumulation of drug-loaded nanoparticles within the tumor interstitium, 51 nanoparticle-based drug delivery has the possibility of overcoming this obstacle.”
BackgroundAdvances and future directions in radiopharmaceutical delivery for cancer treatment
Ailawadhi, S., Pafundi, D., & Peterson, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2472859 · Cited by 6
“Additionally, passive targeting mechanisms, such as the enhanced permeability and retention (EPR) effect, exploit the leaky vasculature and impaired lymphatic drainage of tumors to enhance nanoparticle accumulation within the tumor microenvironment [79].”
Srivastav, A. K., Jaiswal, J., Rajput, P. K., Yadav, U. C. S., Singh, R. K., & Kumar, U. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141845 · Cited by 6
Development and structural analysis of dual-thermo-responsive self-assembled zwitterionic micelles
Zhao, D., Rajan, R., Yusa, S., Nakada, M., & Matsumura, K. (2022) · Materials Advances · doi:10.1039/d1ma01189h · Cited by 6
Rickard, A. G., Mowery, Y., Bassil, A., Rouse, D., Williams, N., Charity, T., Belloni, R., Crouch, B., Ramanujam, N., Stevenson, D., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01855-0 · Cited by 6
“They are also subject to the same limitations: mainly that tumors are known for heterogenous vascular coverage that might limit our ability to image hypoxia across the entire tumor [40].”
In vitro DNA plasmid condensation and transfection through pH-responsive nanohydrogel
Farjadian, F., Behzad‐Behbahani, A., Mohammadi‐Samani, S., & Ghasemi, S. (2022) · Progress in Biomaterials · doi:10.1007/s40204-022-00187-6 · Cited by 6
“On the other hand, nanosized particles like NHs could accumulate in tumoral tissues by enhanced permeation and retention effect (EPR) (Subhan et al. 2021).”
BackgroundPark, S., Kim, J., & Lee, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113910 · Cited by 6
Jin, L., Zhang, S., Wu, Z., Sun, X., Zhou, B., Huang, P.-Q., Fang, M., Li, L., Luo, C., & He, Z. (2023) · Biomaterials Science · doi:10.1039/d3bm01153d · Cited by 5
The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers
Keyvani, V., Mollazadeh, S., Riahi, E., Mahmoudian, R. A., Tabari, M., Lagzian, E., Ghorbani, E., Akbarzade, H., Gholami, A.-S., Gataa, I. S., et al. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128291955240306112558 · Cited by 5
Nanomedicine for ovarian cancer: Enhancing pharmacokinetics and biodistribution
Saddick, S. (2024) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2024.103584 · Cited by 8
Nanoparticle-enabled In Situ drug potency activation for enhanced tumor-specific therapy
Chen, Y., Liu, L., Li, M., Chen, X., Li, Y., Tao, J., & Deng, Y. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106989 · Cited by 5
A Two‐Photon Excited Organic Laser Material for Nano‐Theranostics
Sun, C., Li, J., Yuan, F., Liu, Z., Yang, R., Ye, J., Fu, H., Yao, J., & Zhang, H. (2025) · Laser & Photonics Review · doi:10.1002/lpor.202500299 · Cited by 5
Advancements in Selenium‐Based Nanomedicine: Transforming Cancer Therapy Across Diverse Types
Kesharwani, P., Halwai, K., Gupta, G., Jha, S. K., Goh, K. W., & Abourehab, M. A. S. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500042 · Cited by 5
Tashkandi, J., Brkljača, R., Zhang, M., Hagemeyer, C. E., & Alt, K. (2025) · Nanoscale · doi:10.1039/d5nr00608b · Cited by 5
Nanoparticles in targeted breast cancer therapy — advances and challenges
Lisik, B. P., Sado, A., Rogowska, W., Sroczyński, J., Rogowski, O., & Rogowski, O. (2026) · Oncology in Clinical Practice · doi:10.5603/ocp.106843 · Cited by 7
Çopur, T., Kurt, N., Pezik, E., Yalçın, D., Pehlivan, S. B., & Öner, L. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10051-2 · Cited by 6
“Moreover, cyto - toxicity test results of KT solution, blank, and KT-loaded them from utilizing the enhanced permeability and retention (EPR) effect [57].”
PEG-PLA micelles for targeted codelivery of chemotherapy agents for ovarian cancer
Civril, E., Sanyal, A., & Sanyal, R. (2025) · Journal of Macromolecular Science Part A · doi:10.1080/10601325.2025.2545324 · Cited by 5
“[10] To achieve selective penetration toward the tumor area, the hydrodynamic size of the micellar carrier needs to be below 200 nm. [11] 15–18] This ligand is renowned for targeting integrin receptors, often overexpressed on various cancer cells.”
Integration of Nanotechnology and Nanomaterials in Biomaterials Research
Singh, A. K., Sharma, R., Kujur, V. S., Poddar, M., Kumar, A., Kumar, S., Dhiman, T. K., & Kumar, R. (2025) · Biomaterials Connect · doi:10.69709/biomatc.2025.188313 · Cited by 5
Nano-structured strategies in combatting neurodegeneration
Prasanth, M. I., Mallya, A. R., Cho, W. C. S., & Mundekkad, D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1638668 · Cited by 7
Tan, E., Snee, P. T., & Kalındemirtaş, F. D. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.07.075 · Cited by 5
Soluplus based Polymeric Micelles: A Promising Carrier System for Challenging Drugs
Kaur, M., Rathee, A., Krishna, V. S., & Nagpal, M. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i09.014 · Cited by 5
Tiwari, G., Panda, S., Diyya, A. S. M., Thomas, N. V., Deka, T., Rudrangi, S. R. S., Patel, G. K., & Sharma, P. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01567-y · Cited by 5
“For surface charge analysis by zeta potential, the sample was taken into a folded capillary cell and measured using default parameters [22].”
InfluentialGonzález-Reyna, M. A., Aguilar-Villalva, R., Lopez-Miranda, J. L., Rodríguez, A., Molina, G. A., Juárez‐Moreno, K., Esparza, R., & Estévez, M. (2024) · Nanotechnology · doi:10.1088/1361-6528/ad470d · Cited by 6
“Once the resultant AuNPs-Ac were redispersed at the desired concentration, the amount of organic compound capping the AunNps was evaluated through TGA [ 25 ] resulting in around 15% of the total mass.”
BackgroundMethodInfluentialCanale, J. J., Fernández‐Quiroz, D., Teran‐Saavedra, N. G., Diaz-Galvez, K. R., Gallegos-Tabanico, A., Burgara-Estrella, A., Sarabia-Sainz, H. M., Guzmán-Partida, A. M., Robles–Burgueño, M. D. R., Vázquez–Moreno, L., et al. (2022) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5975 · Cited by 7
“Keywords: nanomedicine, chitosan nanoparticles, drug delivery system, rattlesnake venom, breast cancer treatment Received: 22 October, 2021; revised: 16 December, 2021; accepted: 05 January, 2022; available on-line: 11 February, 2022 ✉e-mail: andreisarabia@gmail.com Acknowledgments of Financial Support: Project was pa…”
BackgroundLatest Delivery Advancements of Lipid Nanoparticles for Cancer Treatment
Chauhan, S., & Nagpal, K. (2024) · Assay and Drug Development Technologies · doi:10.1089/adt.2024.019 · Cited by 6
An Overview of the Application of Gold Nanorods in Photothermal Cancer Therapy
Deinavizadeh, M., Kiasat, A. R., Mirzajani, R., Shafiei, M., Sabaeian, M., & Makvandi, P. (2024) · Materials chemistry horizons. · doi:10.61186/mch.2025.1079 · Cited by 7
“Passive targeting relies on the enhanced permeability and retention (EPR) effect, a phenomenon where nanoparticles accumulate in tumor tissues due to the leaky vasculature and impaired lymphatic drainage of solid tumors [113].”
Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors
Broka, D. M., Klein, S., Shir, A., Schade, B., Saxena, M. T., Dasargyri, A., Jarzębińska, A., Feyter, C. D., Bajic, D., Colecchia, D., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500489122 · Cited by 4
“…demonstrate that the in vivo efficacy of TAR001 is depend ent on EGFR targeting rather than on the enhanced permeability and retention (EPR) effect ( 28 , 29 ), we generated an isogenic cell model from the B16F10 mouse melanoma cell line by stable trans fection with human EGFR cDNA (SI Methods).”
Bari, E., Postuma, I., Miletto, I., Imperio, D., Bortolussi, S., Cansolino, L., Ferrari, C., Liu, Y., Yuan, Z., Torre, M. L., et al. (2025) · Materials Advances · doi:10.1039/d5ma00336a · Cited by 4
Surface-modified organic nanoparticles for lung cancer targeted therapy
Gündel, S. D. S., Alves, A. D. C. S., Dallemole, D. R., Guterres, S. S., & Pohlmann, A. R. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115175 · Cited by 6
Dynarowicz, K., Bartusik‐Aebisher, D., Koszarska, K., Kotlińska, A., & Aebisher, D. (2025) · Life · doi:10.3390/life15101583 · Cited by 7
“Passive transport, using the specificity of the tumor microenvironment: new, dynamically emerging, defective and leaky blood vessels and lack of or limited lymphatic drainage determine the effect of increased permeability and retention (EPR) [105].”
Sun, J., Liu, J., Huang, Y., Zhao, H., Zhao, J.-J., He, S., Zou, T., Zheng, Z. J., Yu, C., & Wei, H. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114907 · Cited by 4
Eldurini, S., Tolba, E., El‐Hady, B. M. A., Ibrahim, A. M., & Shafaa, M. W. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148941 · Cited by 4
Pareek, A., Modi, D., Kapoor, D. U., Prajapati, B. G., Fareed, M., & Alsaidan, O. A. (2026) · International Journal of Polymeric Materials · doi:10.1080/00914037.2025.2610712 · Cited by 5
“[69] Active targeting enhances drug delivery by using ligands that bind to specific receptors overexpressed on tumor cells.”
Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy
Paulo, E. P. D. A., Cabral, L. G. D. S., Poyet, J., & Maria, D. A. (2026) · Molecules · doi:10.3390/molecules31020344 · Cited by 4
“Such multifunctional systems hold the potential to maximize therapeutic efficacy while minimizing off-target effects and systemic toxicity [91,92,94,112].”
Gorbacheva, V. I., Grabovoy, A. S., Marukhina, P. S., Syrocheva, A. O., & Kolesova, E. P. (2026) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.17.27 · Cited by 4
Gharehbaba, A. M., Soltanmohammadi, F., Eskandani, M., & Adibkia, K. (2026) · Results in Engineering · doi:10.1016/j.rineng.2026.110396 · Cited by 4
Tiwary, P., Oswal, K., Varghese, R., & Gupta, P. K. (2026) · Journal of Nanotheranostics · doi:10.3390/jnt7020011 · Cited by 4
“While EPR-mediated drug delivery has been widely recognized, accumulating evidence indicates substantial limitations of this passive approach in humans, owing to pronounced interindividual heterogeneity in tumor type, vascular architecture, and tumor microenvironmental conditions [139,140].”
Application of bismuth sulfide based nanomaterials in cancer diagnosis and treatment
Yang, Z., Wang, L., Zhang, J., Yu, X., & Liu, J. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0207 · Cited by 4
Kimura, T., Okada, K., Morohashi, Y., Matsuda, S., Kato, Y., Mori, M., Kato, H., Matsumoto, T., & Shimoyama, S. (2024) · Pharmaceutical Research · doi:10.1007/s11095-023-03652-4 · Cited by 4
“However, it varies greatly among tumor types, individuals, and metastasis within the same patient [52].”
BackgroundRamalho, M. J., Serra, É., Loureiro, J. A., & Pereira, M. D. C. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105714 · Cited by 4
Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles
Lima, A. F., Justo, G. Z., & Sousa, A. A. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.98 · Cited by 4
Díaz, E., Quezada, V., Cifuentes, J., Morales, N. Y. A., Reyes, L. H., Muñoz-Camargo, C., & Cruz, J. C. (2024) · ACS Omega · doi:10.1021/acsomega.4c07415 · Cited by 4
“2,14 Among various nanomaterials, such as liposomes, nano-particles, dendrimers, and micelles 15 magnetic iron oxide nanoparticles (IONPs) are among the most useful metal nanoparticles in multiple fields, especially in biomedical applications.”
Carbon Quantum Dots Based Materials for Drug Delivery
Pourmadadi, M., Far, B. F., Khajeh, M. M., & Shamsabadipour, A. (2025) · Smart nanomaterials technology · doi:10.1007/978-981-97-8086-0_9 · Cited by 4
Puri, N., Sahane, P., Phatale, V., Khairnar, P., Shukla, S., Priyadarshinee, A., Jain, A., & Srivastava, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143440 · Cited by 4
Emolaga, C. S., Milo, L. C., & Basilia, B. A. (2025) · Sustainable Chemistry One World · doi:10.1016/j.scowo.2025.100091 · Cited by 4
Zhong, H., Tan, W., Zhang, J., Huang, X., Chen, H., Zou, J., Ye, Y. W., Wang, T., Yang, X., Jiang, L., et al. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114704 · Cited by 5
pH-Responsive Modified Dextran Nanogel for Liver Targeted Doxorubicin Delivery
Raeisi, A., Doroudian, M., Rastegari, B., Mohammadi‐Samani, S., Behzad‐Behbahani, A., & Farjadian, F. (2025) · Gels · doi:10.3390/gels11100784 · Cited by 4
“Research has shown that a 40–400 nm nanoparticle size range is appropriate to ensure extended circulation and increased accumulation in the tumor with the EPR, with decreased renal clearance [37].”
Adugna, A., Getinet, M., Amare, G. A., & Jemal, M. (2024) · OpenNano · doi:10.1016/j.onano.2024.100221 · Cited by 4
Malakul, P., & Wada, H. (2025) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2025.131089 · Cited by 4
Tripathi, A., Pandey, V. K., Rustagi, S., Lai, W., & Samrot, A. V. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145365 · Cited by 5
Bharate, G. Y., Qin, H., & Fang, J. Q. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101650 · Cited by 4
“Matsumura [22] in the contest for tumor targeting strategies [23,24].”
BackgroundKalındemirtaş, F. D., Özerkan, D., Kariper, İ. A., & Bulut, H. (2023) · Journal of Fluorescence · doi:10.1007/s10895-023-03180-9 · Cited by 4
“Therefore, passive tumor targeting takes place as this accumulation cannot occur in normal tissue [5].”
BackgroundA Novel Copper Ionophore Nanoshuttle (Winged Cu) for Inducing Cuproptosis in B16 Melanoma Cells
Wu, Y., Chang, Z., Wang, W., Wu, C., Pan, X., & Huang, Z. (2025) · Biomolecules · doi:10.3390/biom15060895 · Cited by 3
“Extensive studies have demonstrated that nanoparticles within the 50–400 nm size range [36] and possessing negative surface charge [37] preferentially accumulate in tumor tissues through the leaky tumor vasculature.”
Mai, N. X. D., Nguyen, H.-V. T., Ta, H. K. T., Vong, L. B., Nguyen, P.-V., Đoàn, T. L. H., & Phan, T. B. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.137803 · Cited by 3
Crintea, A., Munteanu, C., Ilyés, T., Silaghi, C. N., & Craciun, A. M. (2025) · Journal of Functional Biomaterials · doi:10.3390/jfb16090352 · Cited by 3
“Lastly, in aggressive lung cancer types with dense stroma, the relatively large size of some liposomes might lead to limited tumor penetration, affecting drug distribution throughout the tumor mass [39].”
Gomte, S. S., Shewale, R. S., Avaghade, M. M., Vidhate, M. K., & Jain, A. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2584677 · Cited by 3
Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging
Finogenova, Y. А., Skribitsky, V. А., Lipengolts, A. A., Skribitskaya, A. V., Kasianov, A. A., Shpakova, K. E., Laktionov, А. А., Sozaev, I. V., Smirnova, A. V., & Grigorieva, E. Y. (2025) · Nanomaterials · doi:10.3390/nano15241851 · Cited by 3
“By optimizing these parameters, nanoparticles acquire the ability to passively accumulate in subcutaneous and orthotopic tumors via the enhanced permeability and retention (EPR) effect [15,16].”
Wang, Q., Liu, Z., & Jin, K. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s581940 · Cited by 4
Badikol, A. R., Mangu, K., Mundada, A. R., & Rizwanullah, M. (2026) · Nano Trends · doi:10.1016/j.nwnano.2026.100216 · Cited by 3
Ju, R.-J., Wu, F., Tian, Y., Chu, J., Peng, X., & Wang, X. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s387788 · Cited by 3
“The prepared dual sensitization anti-resistant nanoparticles had a hydrodynamic diameter of ~100 nm, which was suitable for accumulating in tumor tissue by enhanced permeability and retention (EPR) effect.(31,32) Nano-drug delivery systems by linking target ligand molecules are often recognized and cleared by the mono…”
BackgroundRepurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics
Movahedi, F., Li, L., & Xu, Z. P. (2023) · Cancer Insight · doi:10.58567/ci02010003 · Cited by 3
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.